Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 6—June 2006

West Nile Virus in Horses, Guatemala

On This Page
Article Metrics
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: West Nile virus (WNV, Flaviviridae: Flavivirus) is emerging as a public health and veterinary concern. Since its introduction into North America in 1999, it has spread rapidly, reaching the Caribbean Basin in 2001, Mexico in 2002, El Salvador in 2003, and Colombia in 2004 (1). However, reports of equine illness and deaths in Latin America are inconclusive. With the exception of viral isolates from a dead bird, a human, and a mosquito pool in Mexico (2,3), all reports of WNV presence in Latin America have relied on serologic evidence. WNV is a member of the Japanese encephalitis serocomplex, which in the Western Hemisphere includes St. Louis encephalitis virus (SLEV) (4). Serologic investigations for WNV in Latin America must use highly specific assays to differentiate WNV infection from potentially cross-reactive viruses such as SLEV or possibly additional unknown viruses. In particular, SLEV is of concern since it was previously isolated from Guatemalan mosquitoes (5).

Alerted by the findings of WNV transmission in the region (1), we collected serum samples from horses from 19 departments of Guatemala from September 2003 to March 2004, to initially estimate the extent of WNV spread and its potential public health risk. Because no animals exhibited signs of neurologic illness at the time of the survey, only healthy horses were sampled. Before 2005, equine WNV vaccines were prohibited and unavailable in Guatemala (Unidad de Normas y Regulaciones, Ministerio de Agricultura Ganadería y Alimentación, Guatemala, pers. comm.); as such, cross-reactivity due to prior vaccination is highly unlikely. Samples were initially tested for WNV-reactive antibodies by using an epitope-blocking enzyme-linked immunosorbent assay (blocking ELISA) (6). The ability of the test sera to block the binding of the monoclonal antibodies to WNV antigen was compared to the blocking ability of control horse serum without antibody to WNV. Data were expressed as relative percentages and inhibition values >30% were considered to indicate the presence of viral antibodies.

A subset of positive samples was further confirmed by plaque-reduction neutralization test (7). Of 352 samples, 149 (42.3%) tested positive with the 3.1112G WNV-specific monoclonal antibody. Of 70 blocking ELISA–positive samples, the neutralization tests indicated the infecting agent was WNV, SLEV, and undifferentiated flavivirus in 9, 33, and 21 samples, respectively. Titers were expressed as the reciprocal of serum dilutions yielding >90% reduction in the number of plaques in a plaque-reduction neutralization test (PRNT90). PRNT90 titers of horses seropositive for WNV ranged from 80 to 320. PRNT90 titers of horses seropositive for SLEV ranged from 40 to 2,560. For the differential diagnosis of samples with neutralizing antibody titers against both WNV and SLEV in this test, a >4-fold titer difference was used to identify the etiologic agent. The undifferentiated flavivirus-reactive specimens had <4-fold difference in cross-neutralization titers. Likely possibilities for the inability to distinguish the infecting virus include previous infection with these or other flaviviruses (previously described or unknown) resulting in elevated cross-reactive titers. The remaining 10% of specimens that tested negative by PRNT probably represent nonneutralizing antibodies in the serum or false positivity in the blocking ELISA.


Thumbnail of Geographic distribution in Guatemala of horses showing previous infections with West Nile virus (WNV), Saint Louis encephalitis virus (SLEV), or undifferentiated flavivirus as confirmed by plaque reduction neutralization test. Each location may have multiple positive horses.

Figure. Geographic distribution in Guatemala of horses showing previous infections with West Nile virus (WNV), Saint Louis encephalitis virus (SLEV), or undifferentiated flavivirus as confirmed by plaque reduction neutralization test. Each location...

Our serologic results provide indirect evidence of past transmission of WNV, SLEV, and possibly other flaviviruses to horses in Guatemala. Although no confirmed cases of WNV-attributed disease have been reported in Central America to date, flavivirus transmission appears to be widely distributed in Guatemala (Figure). Efforts are under way to confirm WNV transmission by viral isolation and to evaluate the impact of WNV on human, horse, and wildlife populations. More information is needed to establish the public health threat of WNV and other zoonotic flaviviruses in the region.



We thank animal owners for permitting sampling, numerous veterinarians of the "Ministerio de Agricultura Ganadería y Alimentación," Alejandra Castillo for technical assistance, and Nicholas Komar for helpful discussions and reviewing the manuscript.

This work was supported in part by Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, "Organismo Internacional Regional de Sanidad Agropecuaria" and by grant U50 CCU820510 from the Centers for Disease Control and Prevention.


Maria Eugenia Morales-Betoulle*Comments to Author , Herber Morales†, Bradley J. Blitvich‡, Ann M. Powers§, E. Ann Davis¶, Robert Klein*, and Celia Cordón-Rosales*

Author affiliations: *Universidad del Valle de Guatemala, Guatemala City, Guatemala; †Ministry of Agriculture and Livestock, Guatemala City, Guatemala; ‡Colorado State University, Fort Collins, Colorado, USA; §Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; ¶US Department of Agriculture-Animal and Plant Health Inspection Service, Guatemala City, Guatemala



  1. Komar  N, Clark  G. West Nile virus activity in Latin America and the Caribbean. Rev Panam Salud Publica. 2006;19:1127. DOIPubMed
  2. Estrada-Franco  JG, Navarro-Lopez  R, Beasley  DW, Coffey  L, Carrara  AS, Travassos da Rosa  A, West Nile virus in Mexico: evidence of widespread circulation since July 2002. Emerg Infect Dis. 2003;9:16047.PubMed
  3. Elizondo-Quiroga  D, Davis  TC, Fernandaz-Salas  I, Escobar-Lopez  R, Olmos  DV, Gastalum  LCS, West Nile virus isolation in human and mosquitoes, Mexico. Emerg Infect Dis. 2005;11:144952.PubMed
  4. Calisher  CH, Karabatsos  N, Dalrymple  JM, Shope  RE, Porterfield  JS, Westaway  EG, Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. 1989;70:3743. DOIPubMed
  5. Cupp  EW, Scherer  WF, Lok  JB, Brenner  RJ, Dziem  GM, Ordonez  JV. Entomological studies at an enzootic Venezuelan equine encephalitis virus focus in Guatemala, 1977–1980. Am J Trop Med Hyg. 1986;35:8519.PubMed
  6. Blitvich  BJ, Bowen  RA, Marlenee  NL, Hall  RA, Bunning  ML, Beaty  BJ. Epitope-blocking enzyme-linked immunosorbent assays for detection of West Nile virus antibodies in domestic mammals. J Clin Microbiol. 2003;41:26769. DOIPubMed
  7. Beaty  BJ, Calisher  CH, Shope  RE. Arboviruses. In: Lennette EH, Lennette DA, Lennette ET, editors. Diagnostic procedures for viral, rickettsial, and chlamydial infections. 7th ed. Washington: American Public Health Association; 1995. p. 189–212.




Cite This Article

DOI: 10.3201/eid1206.051615

Related Links


Table of Contents – Volume 12, Number 6—June 2006


Please use the form below to submit correspondence to the authors or contact them at the following address:

Address for correspondence: Maria Eugenia Morales-Betoulle, Arbovirology Laboratory, CDC-CAP, Universidad del Valle de Guatemala, Guatemala City, Guatemala

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.


Page created: January 04, 2012
Page updated: January 04, 2012
Page reviewed: January 04, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.